Clinical trial
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease
NCT02174939 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease
- Lead sponsor
- National Cheng-Kung University Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- February 28, 2014
- Completion date
- December 31, 2017
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.